Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Crawford James C 2. Date of Event Requiring Statement (Month/Day/Year) 01/28/2025 3. Issuer Name and Ticker or Trading Symbol Aspira Women's Health Inc. [AWH] (Last) (First) (Middle) C/O ASPIRA WOMEN'S HEALTH INC, 12117 BEE CAVES RD, BLDG 3-100 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Vice President of Finance 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) AUSTIN,, TX 78738 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	(1)	03/31/2032	Common Stock	400	$15.6	D
Employee Stock Option (Right to Buy)	(2)	01/20/2033	Common Stock	1,000	$7.5	D
Employee Stock Option (Right to Buy)	(3)	02/08/2033	Common Stock	666	$8.7	D
Employee Stock Option (Right to Buy)	02/08/2023	02/08/2033	Common Stock	333	$8.7	D
Employee Stock Option (Right to Buy)	(4)	02/14/2034	Common Stock	1,600	$4.87	D
Employee Stock Option (Right to Buy)	(5)	07/03/2034	Common Stock	3,500	$0.94	D
Employee Stock Option (Right to Buy)	(6)	08/08/2034	Common Stock	25,000	$1.17	D
Employee Stock Option (Right to Buy)	11/21/2024	11/21/2034	Common Stock	1,000	$0.75	D
Employee Stock Option (Right to Buy)	(7)	06/24/2031	Common Stock	800	$88.5	D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Crawford James C C/O ASPIRA WOMEN'S HEALTH INC 12117 BEE CAVES RD, BLDG 3-100 AUSTIN,, TX 78738			Vice President of Finance

Signatures

/s/ James Crawford		03/24/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The option vests in four equal annual installments beginning on March 31, 2023.
(2)	The option vests in four equal annual installments beginning on January 20, 2024.
(3)	The option vests in three equal annual installments beginning on February 8, 2024.
(4)	The option vests in three equal annual installments beginning on February 14, 2025.
(5)	The option vests 100% on July 3, 2025.
(6)	The option vests in 48 equal monthly installments beginning on September 8, 2024.
(7)	The option vests in four equal annual installments beginning on May 24, 2022.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.